Urocortin and inflammation: Confounding effects of hypotension on measures of inflammation

NeuroImmunoModulation

Volumn 6, Issue 3, 1999, Pages 182-186

  Torpy, David J ^a   Webster, Elizabeth L ^a   Zachman, E Keith ^a   Aguilera, Greti ^a   Chrousos, George P ^a  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

Blood pressure; Inflammation; Urocortin

Indexed keywords

CARRAGEENAN; CORTICOTROPIN RELEASING FACTOR RECEPTOR; HYDRALAZINE; UROCORTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTERIAL PRESSURE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; EXTRAVASATION; HEAT; HYPOTENSION; INFLAMMATION; LEUKOCYTE COUNT; MALE; NONHUMAN; PAW EDEMA; PRIORITY JOURNAL; RAT; RECEPTOR UPREGULATION;

EID: 0032908055     PISSN: 10217401     EISSN: None     Source Type: Journal    
DOI: 10.1159/000026380     Document Type: Article

References (16)

1. Vaughan J, Donaldson C, Bittencourt J, Pcrrin MH, Lewis K, Sutton S, Chan R, Turnbull AV, Lovejoy D, Rivier C, Rivier J, Sawchenko PE, Vale WW: Urocortin, a mammalien neuropeptide related to fish urotensin 1 and to corticotropin-releasing factor. Nature 1995;378:287-292.
2. Donaldson CJ, Sutton SW, Perrin MH, Corrigan AZ, Lewis KA, Rivier JE, Vaughan JM, Vale WW: Cloning and characterization of human urocortin. Endocrinology 1996;137:2167-2170.
3. Turnbull AV, Vale W, Rivier C: Urocortin, a corticotropin-releasing factor-related mammalian peptide, inhibits edema due to thermal injury in rats. Eur J Pharmacol 1996;303:213-216.
4. Spina M, Merlo-Pich E, Chan RK, Basso AM, Rivier J, Vale W, Koob GF: Appetite suppressing effects of urocortin, a CRF-related neuropeptide. Science 1996;273:1561-1564.
5. Gao GC, WEi ET: Xenopsin, neurotensin, neurotensin (8-13) inhibit vascular leakage in rats after tissue injury. J Pharmacol Exp Ther 1993; 265:619-625.
6. Udelsman R, Galluci WT, Bacher J, Loriaux DL, Chrousos GP: Hemodynamic effects of corticotropin releasing hormone in the anesthetized cynomolgus monkey. Peptides 1986;7: 465-471.
7. Karalis K, Sano H, Redwine J, Listwak S, Wilder RL, Chrousos GP: Autocrine or paracrine inflammatory effects of corticotropin-releasing hormone in vivo. Science 1991;254: 421-423.
8. Vale W, Spiess J, Rivier C, Rivier J: Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. Science 1981;213: 1394-1397.
9. Chrousos GP, Gold PW: The concepts of stress and stress system disorders. Overview of physical and behavioral homeostasis. J Am Med Assoc 1992;267:1244-1252.
10. Parkes DG, Vaughan J, Rivier J, Vale W, May CN: Cardiac inotropic actions of urocortin in conscious sheep. Am J Physiol 1997;272: H2115-H2122.
11. Wei AT, Thomas HA: Anti-inflammatory peptide agonists. Annu Rev Pharmacol Toxicol 1993;33:91-108.
12. Hargreaves KM, Dubner R, Costello AH: Corticotropin releasing factor (CRF) has a peripheral site of action for antinociception. Eur J Pharmacol 1989;170:275-279.
13. Mastorakos G, Bouzas EA, Silver PB, Sartani G, Friedman TC, Chan CC, Caspi RR, Chrousos GP: Immune corticotropin-releasing hormone is present in the eyes of and promotes experimental autoimmune uveoretinitis in rodents. Endocrinology 1995;136:4650-4658.
14. Scopa CD, Mastorakos G, Friedman TC, Melachrinou M, Merino MJ, Chrousos GP: Presence of immunoreactive corticotropin releasing hormone in thyroid lesions. Am J Pathol 1994; 145:1159-1167.
15. Webster EL, Lewis DB, Torpy DJ, Zachman EK, Rice KC, Chrousos GP: In vivo and in vitro characterization of antalarmin, a nonpeptide corticotropin-releasing hormone (CRH) receptor antagonist: Suppression of pituitary ACTH release and peripheral inflammation. Endocrinology 1996;137:5747-5750.
16. Theoharides TC; Singh LK, Boucher W, Pang X, Letoumeau R, Webster E, Chrousos G: Corticotropin-releasing hormone induces skin mast cell degranulation and increased vascular permeability, a possible explanation for its proinflammatory effects. Endocrinology 1998; 139:403-413.